A model for estimating cirrhosis in patients with type 1 autoimmune hepatitis

Hepatology Research

Volumn 38, Issue 7, 2008, Pages 658-663

  Miyake, Yasuhiro ^a   Iwasaki, Yoshiaki ^a   Terada, Ryo ^a   Nagano, Takuya ^b   Kobashi, Haruhiko ^a   Sakaguchi, Kohsaku ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

AST ALT ratio; Autoimmunehepatitis; Cirrhosis; Immunoglobulin A; Platelet

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN A;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TYPE 1 AUTOIMMUNE HEPATITIS; VALIDATION STUDY;

EID: 44649151213     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00329.x     Document Type: Article

References (29)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
2. Toda G. A nationwide survey of autoimmune hepatitis. Annual Report. Intractable Hepatitis Research Committee of Japanese Ministry of Health and Welfare. 1999; 8-11. (In Japanese.)
3. Miyake T, Miyaoka H, Abe M etal. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006; 36: 139-42.
4. Ryder SD, Koskinas J, Rizzi PM et al. Hepatocellular carcinoma complicating autoimmune hepatitis: Role of hepatitis C virus. Hepatology 1995; 22: 718-22.
5. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944-8.
6. Yamazaki K, Kamiyama T, Shiba S et al. An aged male patient with autoimmune hepatitis complicated by hepatocellular carcinoma. Intern Med 1999; 38: 422-5.
7. Watanabe M, Moritani M, Hamamoto S etal. Hepatocellular carcinoma complicating HCV-negative autoimmune hepatitis without corticosteroid therapy. J Clin Gastroenterol 2000; 30: 445-6.
8. Hori K, Fukuda Y, Tomita T etal. Hepatocellular carcinoma complicating autoimmune hepatitis without either hepatitis C viral infection or corticosteroid therapy. J Gastroenterol 2003; 38: 197-9.
9. Hardee JT, Breth GF, El-Serag HB. Hepatocellular carcinoma associated with autoimmune hepatitis. J Clin Gastroenterol 2003; 37: 271-2.
10. Sakaguchi T, Nakamura S, Suzuki S etal. Hepatocellular carcinoma associated with lupoid hepatitis: A review of Japanese reports. Surg Today 1995; 25: 838-42.
11. Nishiyama R, Kanai T, Abe J et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg 2004; 11: 215-19.
12. Miyake Y, Sakaguchi K, Tanaka H etal. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern Med 2005; 44: 949-53.
13. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
14. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-64.
15. Lok AS, Ghany MG, Goodman ZD et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology 2005; 42: 282-92.
16. Lackner C, Struber G, Liegl B et al. Comparison and validation of simple non-invasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
17. Kelleher TB, Mehta SH, Bhaskar R et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 2005; 43: 78-84.
18. Alvarez F, Berg PA, Bianchi FB et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
20. van de Wiel A, van Hattum J, Schuurman HJ, Kater L. Immunoglobulin A in the diagnosis of alcoholic liver disease. Gastroenterology 1988; 94: 457-62.
21. Watt K, Uhanova J, Gong Y etal. Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 251-6.
22. Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol 2001; 13: 317-23.
23. Taniguchi H, Iwasaki Y, Fujiwara A et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol 2006; 21: 281-7.
24. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-52.
25. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
26. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: Evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985; 5: 367-75.
27. Nalpas B, Vassault A, Le Guillou A et al. Serum activity of mitochondrial aspartate aminotransferase: A sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984; 4: 893-6.
28. Czaja AJ, Freese DK. American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
29. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39: 1631-8.